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Abstract : Some studies have reported that adrenomedullin （AM） is involved in 
diabetes mellitus （DM） associated with pancreatic cancer.  Therefore, in this study 
we investigated the relationship between diabetes and AM expression in patients 
with pancreatic cancer.  We examined 48 biopsies and 26 surgical resections from 
74 patients with histologically diagnosed pancreatic cancer.  Patients were classied 
into either DM or non-DM groups.  The immunohistochemical expression of AM 
and various clinicopathological factors were compared between the two groups.  
Among the biopsy cases, 21 were classified as DM and 27 as non-DM.  AM 
expression in pancreatic cancer cells was significantly lower in the DM group  
（p＝0.03）.  No signicant differences were noted in age, body mass index, tumor 
diameter or location, serum CA19-9, amylase, or C-reactive protein levels, pancreatic 
ductal dilatation, portal vein invasion, clinical stage, or histological differentiation 
between the DM and non-DM groups.  The proportion of men was signicantly 
lower in the DM group （p＝0.04）, as was the frequency of liver metastasis at 
diagnosis （p＝0.03）.  Among the resection cases, 13 were classied as DM and 13 
as non-DM.  There were no signicant differences in AM expression in pancreatic 
cancer cells between the two groups.  However, marked AM expression was 
observed in the inammatory cells and broblasts of the tumor stroma in all cases.  
In addition, the inammatory response in the tumor stroma tended to be stronger 
in the DM group.  Although the present study failed to nd a positive correlation 
between diabetes and AM expression in pancreatic cancer cells, the results indicate 
that AM expression in stromal cells may be more closely related to the development 
of DM in pancreatic cancer patients.
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Introduction
　The relationship between diabetes mellitus （DM） and pancreatic cancer （PC） has long been 
considered.  The prevalence of diabetes in PC patients is high, ranging from approximately 40％ 
to 55％1-3）.  Long-standing diabetes is regarded as a risk factor for PC, whereas PC is thought 
to cause diabetes and glucose tolerance.  Diabetes frequently improves after surgical resection of 
PC 2，4）, and Pannala et al reported that diabetes improved after pancreatectomy in 57％ of PC 
patients with new-onset diabetes 2）.  These facts suggest that PC itself may cause diabetes, but 
the underlying mechanism remains unclear.
　One possible mechanism is thought to be the secretion, by tumors, of diabetogenic products 
that cause diabetes 5）, including adrenomedullin （AM）, islet amyloid polypeptide, and S-100A8 
N-terminal peptide 6，7）.  AM, a 52-amino acid multifunctional hormone, was originally identied 
as a hypotensive peptide isolated from pheochromocytoma and subsequently shown to exert 
proliferative and proangiogenic effects8）.  AM inhibits insulin secretion from pancreatic islets and 
causes glucose tolerance in vivo and in vitro 9）.  Recent studies have reported that AM expression 
in PC cells is a likely candidate for the induction of diabetes in patients with PC 5，7，10）.  The 
main purpose of the present study was to investigate the relationship between the presence or 
absence of diabetes and the expression of AM in PC cells.
Materials and methods
　The study was performed on 48 patients who had undergone a pancreatic biopsy by endoscopic 
ultrasound-guided ne needle aspiration and 26 who had undergone pancreatic surgical resection 
between 2014 and 2017 at the Showa University Fujigaoka Hospital.  All patients had been 
histopathologically diagnosed with typical pancreatic cancer （tubular adenocarcinoma）.  Patients 
were divided into two groups based on serum HbA1c levels at the time of diagnosis and their 
history of diabetes : （i） a DM group, with HbA1c ≥ 6.5％ and no history of diabetes or HbA1c ≥
8.0％ and a history of diabetes ; and （ii） a non-DM group without these abnormalities.  Among 
the biopsied cases, 21 were classied as DM and 27 as non-DM ; among the resected cases, 13 
were classied as DM and 13 as non-DM.
　Clinicopathological features （i.e. patient age, gender, body mass index ［BMI］, tumor size, loca-
tion, serum concentrations of carbohydrate antigen 19-9 ［CA19-9］, amylase, and C-reactive pro-
tein ［CRP］, dilatation of the pancreatic duct, invasion to the portal vein, liver metastasis, clinical 
stage, and histological differentiation） were investigated in the patients who underwent pancreatic 
biopsy and were compared between the DM and non-DM groups.  Tumor size, location, dilata-
tion of the pancreatic duct, invasion to the portal vein, and liver metastasis were evaluated by 
computed tomography （CT） or magnetic resonance imaging （MRI）.  Clinical stage was classied 
according to the criteria issued by the Japan Pancreas Society 11）.
　For the immunohistological investigation of AM expression, 3-µm sections were obtained from 
each formalin-xed, parafn-embedded block.  Immunohistochemical staining was performed using 
the avidin–biotin complex detection system with a BEKCHMARK automated immunostaining 
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device （Ventana Medical Systems, Tucson, AZ, USA）.  A rabbit anti-human AM polyclonal 
antibody （200-fold dilution ; abcam, Cambridge, UK） was used.  The staining intensity of AM 
expression in tumor cells was classied as mild （0）, moderate （1＋）, or severe （2＋）, as shown 
in Fig. 1, and was compared between the DM and non-DM groups for both biopsied and 
resected cases.
Fig. 1.  Immunohistological expression of adrenomedullin in pancreatic cancer cells was categorized 
into three grades based on staining intensity : （A） mild （0）, （B） moderate （1＋）, and 
severe （2＋）. Representative images of each grade are shown （original magnification×400）.
Fig. 2.  Immunohistological expression of adrenomedullin （AM） in （A） inflammatory 
cells and （B） fibroblasts in the tumor stroma （original magnification ×
400）. Marked AM expression was seen in both inflammatory cells （A） and 
fibroblasts （B）, and it was particularly prominent in lymph follicles.
Fig. 3.  The degree of inflammation of the tumor stroma was categorized into three grades : （A） mild （0）, 
（B） moderate （1＋）, and severe （2＋）. Representative images of each grade are shown （original 
magnification×100 ; hematoxylin and eosin staining）. There was scant inflammatory cell infiltration 
in the mild group （A）, whereas prominent infiltration forming many lymph follicles was seen in 
the severe group （C）. Intermediate infiltration was seen in the moderate group （B）.
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　In surgical specimens, AM expression was observed in the tumor stroma （Fig. 2） and the 
degree of inammation was investigated and classied as follows : mild （0）, scant inltration of 
inammatory cells ; moderate （1＋）, intermediate inltration ; and severe （2＋）, prominent inl-
tration of inammatory cells containing many lymph follicles （Fig. 3）.  The degree of inamma-
tion was compared between the DM and non-DM groups.  In addition, we investigated whether 
there were signicant relationships between serum HbA1c, diabetic status （i.e. DM or non-DM 
group）, the degree of AM expression in tumor cells, and the degree of inammation.  Pathologi-
cal scoring was performed by two pathologists （H.I. and N.O.） in a blinded manner.  Statistical 
analyses were performed using the χ2 test, Fisher’s exact test, or Wilcoxon’s rank sum test. 
Two-tailed p＜ 0.05 was considered signicant.
　The present study was a retrospective study, and consent was obtained by opt-out.  Informa-
tion regarding the study was posted on the Showa University Fujigaoka Hospital homepage. 
Subjects were guaranteed the opportunity to opt-out of the study.  Approval for this study was 
obtained from the Ethics Committee at Showa University Fujigaoka Hospital （Permission no. 
F2017C62）.
Results
Clinicopathological comparisons between the DM and non-DM groups （pancreatic biopsies）
　Clinicopathological factors in the DM （n＝21） and non-DM （n＝27） groups were compared 
for biopsy cases （Table 1）.  The non-DM group included three patients who had a history of 
diabetes but did not meet the criteria of the DM group.  In the DM and non-DM groups, 
Table 1.  Clinicopathological characteristics of the diabetes mellitus （DM） and non-DM groups of patients 
who underwent pancreatic biopsy by endoscopic ultrasound-guided fine needle aspiration
DM group （n＝21） Non-DM group （n＝27） p-value
Age （years） 71 ［65.5-75］ 72 ［68-79］ 0.3
Male  7 （33） 17 （63） 0.04
BMI （kg/m2） 21.2 ［18.6-21.9］ 20.6 ［17.4-22.1］ 0.63
Tumor size （mm） 33 ［20-40］ 34 ［29-47］ 0.65
Location pancreatic head 12 （57） 10 （37） 0.17
CA19-9 （U/ml） 724 ［107-2,840］ 1,144 ［292-9,640］ 0.29
Amylase （IU/l） 58 ［45.5-107］ 72 ［50-118］ 0.48
CRP （mg/dl） 0.14 ［0.04-0.50］ 0.12 ［0.05-0.77］ 0.61
Dilatation of pancreatic duct ≥ 5 mm 11 （52）  9 （33） 0.18
Invasion to portal vein  4 （19）  9 （33） 0.27
Liver metastasis  5 （24） 15 （56） 0.03
Clinical Stage Ⅳ 14 （67） 21 （78） 0.39
Poorly differentiated histologically  3 （14） 2 （7） 0.64
Data are expressed as the median ［25th-75th percentile］ or as the number of patients （％）.
BMI, body mass index ; CA19-9, carbohydrate antigen 19-9 ; CRP, C-reactive protein.
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respectively, the median age was 71 and 72 years, 33％ and 63％ of patients were male, median 
BMI was 21.2 and 20.6 kg/m2, and median tumor diameter was 33 and 34 mm.  When the tumor 
location was classied into pancreatic head versus body and tail, 57％ and 37％ of tumors were 
located in the head in the DM and non-DM groups, respectively.  In the DM and non-DM 
groups, respectively, median serum CA19-9 was 724 and 1,144 U/ml, median amylase was 58 and 
72 IU/l, and median CRP levels were 0.14 and 0.12 mg/dl.  The number of signicant dilatations 
（≥ 5 mm in diameter） of the main pancreatic duct was 11 （52％） and 9 （33％） in the DM and 
non-DM groups, respectively, whereas the number of patients in the DM and non-DM groups 
with invasion to the portal vein was 4 （19％） and 9 （33％）, respectively, and 5 （24％） and 15 
（56％） patients, respectively, had liver metastases.  The number of clinical Stage Ⅳ cases in the 
DM and non-DM groups was 14 （67％） and 21 （78％）, respectively, and there were 3 （14％） 
and 2 （7％） cases with poorly differentiated adenocarcinoma in these two groups, respectively. 
Signicant differences were found with regard to gender （p＝0.04） and liver metastasis （p＝0.03）. 
The DM group tended to be more frequently diagnosed with PC due to new-onset diabetes or 
elevated blood glucose before developing liver metastasis.
AM expression in tumor cells from pancreatic biopsy or surgically resected specimens
　Immunohistochemical analysis revealed uniform AM staining throughout the lesions in all cases, 
but of varying degree.  In biopsy cases, mild （0）, moderate （1＋）, and severe （2＋） AM expression 
was found in tumor cells in 6 （28％）, 10 （48％）, and 5 （24％） cases in the DM group, respectively, 
compared with 2 （7％）, 12 （45％）, and 13 （48％） cases in the non-DM group （Fig. 4A）.  AM 
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Fig. 4. Comparison of adrenomedullin （AM） expression in tumor cells from 
specimens obtained by （A） pancreatic biopsy or （B） surgical resection and 
separated into diabetes mellitus （DM） and non-DM groups. AM expression 
was classified as follows : 0, mild ; 1＋, moderate ; and 2＋, severe. AM 
expression in tumor cells of specimens obtained by pancreatic biopsy was 
significantly lower in the DM than in the non-DM group （p＝0.03）, but 
there was no significant difference between these two groups for samples 
obtained by surgical resection.
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resected specimens, there were 4 （31％）, 4 （31％）, and 5 （38％） cases of mild （0）, moderate （1＋）, 
and severe （2＋） AM expression in tumor cells, respectively, in the DM group, compared with 
4 （31％）, 6 （46％）, and 3 （23％） cases in the non-DM group （Fig. 4B）.  There were no signi-
cant differences in AM staining intensity between the two groups （p＝0.64）.
Inammation of the tumor stroma in surgically resected specimens
　Significant AM expression was observed in inflammatory cells and fibroblasts in the tumor 
stroma.  In particular, AM expression was prominent in lymph follicles.  There were 2 （15％）, 3 
（23％）, and 8 （62％） cases of mild （0）, moderate （1＋）, and severe （2＋） inammation of the 
tumor stroma, respectively, in the DM group, compared with 3 （23％）, 6 （46％）, and 4 （31％） 
in the non-DM group （Fig. 5）.  These observations suggest that the inammatory response of 
the tumor stroma tended to be stronger in the DM than in the non-DM group, although the 
difference was not statistically signicant （p＝0.18）.
Relationships between serum HbA1c, group, the degree of AM expression in tumor cells, and the 
degree of inammation in surgically resected specimens
　As indicated in Table 2, there were no signicant differences in serum HbA1c, DM group, and 
inammation of the tumor stroma between different grades of AM expression in tumor cells.  In 
addition, there were no signicant differences in serum HbA1c, DM group, and AM expression 
in tumor cells between different grades of inammation of the tumor stroma （Table 3）.  How-
ever, there was a tendency for a greater number of cases in the DM group to exhibit stronger 
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Fig. 5.  Comparison of inflammation of the tumor stroma 
in specimens obtained by surgical resection between 
the diabetes mellitus （DM） and non-DM groups. 
Inflammation of the tumor stroma was categorized 
as follows : 0, mild ; 1＋, moderate ; and 2＋, severe. 
Although there was no significant difference between 
the two groups, the degree of inflammation tended to 
be greater in the DM than in the non-DM group.
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Discussion
　The underlying mechanism and pathogenesis of PC-induced diabetes remain unclear.  Previous 
reports have suggested direct destruction of islet cells or a decrease in the number of islet cells 
as a result of PC invasion and/or PC-associated obstructive pancreatitis and brosis12，13）.  How-
ever, diabetes frequently improves after surgical resection of PC, and even small tumors cause 
glucose tolerance ; therefore, it seems difcult to attribute the pathogenesis of DM only to the 
destruction of or a decrease in the number of islet cells 2，7）.  The biopsy case study reported 
herein also showed no signicant differences in factors related to tumor development, such as 
tumor size and dilatation of the pancreatic duct, between the DM and non-DM groups.
Table 2.  Relationship between adrenomedullin expression in tumor cells and HbA1c, diabetes status, 
and stromal inflammation in surgically resected cases
AM expression in tumor cells
p-valueA
0 （n＝8） 1＋ （n＝10） 2＋ （n＝8）
HbA1c （％） 6.4 ［6.0-9.8］ 6.9 ［5.8-11.8］ 7.4 ［6.2-9.3］ 0.66
DM group 4 （50） 4 （40） 5 （63） 1.00
Inflammation of tumor stroma 0.53
　0 2 （25） 1 （10） 2 （25）
　1＋ 1 （12.5） 6 （60） 2 （25）
　2＋ 5 （62.5） 3 （30） 4 （50）
Data are expressed as the median ［25th-75th percentile］ or as the number of patients （％）.
Adrenomedullin （AM） expression and inflammation of the tumor stroma were categorized as 
follows : 0, mild ; 1＋, moderate ; and 2＋, severe.
AP-values are for comparisons of Grade 0 expression vs Grades 1＋ and 2＋.
DM, diabetes mellitus.
Table 3.  Relationship between stromal inflammation and HbA1c, diabetes status, and adrenomedullin 
expression in tumor cells in surgically resected cases
Inflammation of tumor stroma
p-valueA
0 （n＝5） 1＋ （n＝9） 2＋ （n＝12）
HbA1c （％） 6.2 ［5.8-6.6］ 7.0 ［6.2-7.7］ 9.1 ［6.0-11.0］ 0.18
DM group 2 （40） 3 （33） 8 （67） 0.12
AM expression in tumor cells 0.64
　0 2 （40） 1 （11） 5 （42）
　1＋ 1 （20） 6 （67） 3 （25）
　2＋ 2 （40） 2 （22） 4 （33）
Data are expressed as the median ［25th-75th percentile］ or as the number of patients （％）.
Adrenomedullin （AM） expression and inflammation of the tumor stroma were categorized as 
follows : 0, mild ; 1＋, moderate ; and 2＋, severe.
AP-values are for comparisons of Grade 0 expression vs Grades 1＋ and 2＋.
DM, diabetes mellitus.
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　Several diabetogenic tumor-secreted products are hypothesized to be involved in PC-associated 
diabetes 6，7）, including AM 5，7，10，14）.  AM is a multifunctional hormone expressed in various tissues 
of the human body.  In the pancreas, AM receptors are found on β-cells, and AM expression is 
found in pancreatic polypeptide cells of the islets 15）.  Furthermore, AM inhibits insulin secretion 
from islets and causes glucose tolerance in in vivo and in vitro in rat models 9）.
　Ramachandran et al 16） showed that AM is expressed in PC and it stimulates cell proliferation 
and invasion in an autocrine manner via the AM receptor 16）.  Aggarwal et al 10）, using both in 
vivo and in vitro experiments, showed that AM is upregulated in patients with PC and it medi-
ates PC-induced inhibition of insulin section in β-cells.  AM levels are higher in patients with 
PC who developed diabetes compared to those who did not 10）.  In contrast to our expectations, 
in the present study we failed to nd a signicantly higher AM expression in the DM group, in 
either the biopsy or resection cases ; rather, we found that the AM expression was signicantly 
lower in the DM than in the non-DM group.
　To determine the cause of this unexpected result, we focused on AM expression in surgically 
resected specimens ; in these specimens, in almost all cases, AM expression was more prominent 
in the inammatory cells （especially lymph follicles） and broblasts of the tumor stroma than 
in PC cells.  Although the differences were not signicant, we did nd a stronger inammatory 
response in the DM than in the non-DM group, suggesting that AM expression in response to 
inammation may be more closely related to the development of diabetes in PC patients, as 
reported previously 6，7，17）.  Regarding broblasts, Bhowmick et al 18） showed that stromal broblasts 
in tumors are biologically distinct from normal broblasts, and Benyahia et al 19） reported that 
stromal broblasts in breast cancer promote tumor growth and angiogenesis through AM secre-
tion.  We expect that the AM expression of stromal broblasts in PC will be found to have 
multiple functions and to be associated with the onset of diabetes.
　In conclusion, the present study failed to nd a positive correlation between diabetes and AM 
expression in PC cells.  Conversely, the inammatory response in the tumor stroma tended to be 
stronger in the DM group, although the difference was not statistically signicant.  Therefore, the 
ndings of the present study indicate that AM expression in inammatory tissues may be one of 
the potential mechanisms by which PC induces diabetes.
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